KRAS and neoplasm: Although a degree of variability in the fitness conferred by specific mutations of oncogenes is expected, for example, G12D variants compared with A146T in KRAS (44), that complete loss of the β-catenin–binding 20AARs in tumor-suppressive APC does not lead to maximal cancer risk is remarkable.